Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers

Summary What is known and Objective:  Ivabradine is a novel heart rate‐lowering agent that selectively and specifically inhibits the depolarizing cardiac pacemaker I f current in the sinus node. Our objective was to evaluate a possible pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. Methods:  The study consisted of two periods: Period 1 (Reference), when each volunteer received a single dose of 10 mg ivabradine and Period 2 (Test), when each volunteer received a single dose of 10 mg ivabradine and 400 mg carbamazepine. Between the two periods, the subjects were treated for 15 days with a single daily dose of 400 mg carbamazepine. Plasma concentrations of ivabradine were determined during a 12‐h period following drug administration, using a high‐throughput liquid chromatography with mass spectrometry analytical method. Pharmacokinetic parameters of ivabradine administered in each treatment period were calculated using non‐compartmental and compartmental analysis to determine if there were statistically significant differences. Results and Discussion:  In the two periods of treatments, the mean peak plasma concentrations ( C max ) were 16·25 ng/mL (ivabradine alone) and 3·69 ng/mL (ivabradine after pretreatment with carbamazepine). The time taken to reach C max , t max , were 0·97 and 1·14 h, respectively, and the total areas under the curve (AUC 0‐∞ ) were 52·49 and 10·33 ng h/mL, respectively. These differences were statistically significant for C max and AUC 0‐∞ when ivabradine was administered with carbamazepine, whereas they were not for t max , half‐life and mean residence time. What is new and Conclusion:  TCarbamazepine interacts with ivabradine in healthy volunteers, and lowers its bioavailability by about 80%. This magnitude of effect is likley to be clinically significant.